Case Report

Carbamazepine-Induced Toxic Epidermal Necrolysis Managed by Mobile Teledermatology in COVID-19 Pandemic in Rural Nepal

Vikash Paudel and Deepa Chudal

National Medical College, Birgunj, Parsa, Nepal
Nepal Police Hospital, Kathmandu, Nepal

Correspondence should be addressed to Vikash Paudel; vikashpoudel@iom.edu.np

Received 17 September 2020; Accepted 28 October 2020; Published 10 November 2020

Academic Editor: Jacek Cezary Szepietowski

Copyright © 2020 Vikash Paudel and Deepa Chudal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Toxic epidermal necrolysis (TEN), also known as Lyell’s syndrome [1], is a potentially life-threatening dermatological emergency with high mortality [2]. Though TEN is less common in dermatological practice, carbamazepine is one of the commonest culprits among all the drugs [3]. Here, we present a case of carbamazepine induced toxic epidermal necrolysis in a young female from rural Nepal, who was successfully treated using simple mobile teledermatology in COVID-19 pandemic.

2. Case Report

This is a story of a 12-year-old female from rural Nepal who developed rapidly progressive generalized rash along with mild fever and headache. She was diagnosed with seizure disorder 2 weeks prior to the current illness and was prescribed carbamazepine at the dose of 200 mg daily. On the 14th day of carbamazepine, she developed those rashes which were purpuric, some of which later turned to blisters, dusky colored, itchy to start with which later were tender, and covered almost 40% of body surface area covering trunk and face with involvement of oral mucosa and eye. It was associated with swelling of the face and mild fever.

As the whole country was under lockdown due to COVID-19 crisis, it was impossible for the rural area patient to visit a dermatologist. Thus, with the help of paramedics staff in a community health center and mobile teledermatology, the patient was diagnosed as carbamazepine-induced toxic epidermal necrolysis and treated successfully with good outcome.
The clinical impression of toxic epidermal necrolysis due to carbamazepine was made after taking detail history and serial clinical findings in video calls and photos sent in the mobile device.

Regarding the management of the patient in rural setting, carbamazepine was stopped immediately. She was supplemented with a rapidly tapering dose of intravenous hydrocortisone along with fexofenadine, mupirocin ointment, and moisturizer. The erosions were smeared with mupirocin and paraffin gauges. Supportive treatment given included parenteral analgesics for pain management and intravenous fluids. The patient was advised for better nutrition for healing of the wound by giving adequate carbohydrate, high-protein diet, and vitamin supplements. She was switched over to oral prednisolone once the lesions started healing after five days. Later on, prednisolone was slowly tapered slowly over two weeks. The lesions healed with postinflammatory hyperpigmentation (Figures 2 and 3).

3. Discussion

TEN is a severe cutaneous adverse drug reaction and life-threatening dermatological emergency [1]. The common causes are mostly drugs like sulphamides, nonsteroidal anti-inflammatory drugs (NSAIDs), beta-lactum antibiotics, quinolones, nevirapine, antitubercular drugs, allopurinol, and aromatic antiepileptics like carbamazepine, phenobarbital, and phenytoin [3]. The time duration of TEN after initiating carbamazepine is usually less than 3 weeks. Our patient presented with generalized erythema and peeling of the skin with mucosal erosions two weeks after initiating carbamazepine.

Recently, carbamazepine was found to be a common drug causing TEN [4]. The pathogenesis of TEN is cytotoxic destruction and apoptosis of keratinocytes. The proapoptotic molecules like TNF-α, interferon-γ, and inducible nitric oxide synthase may link drug-induced immune responses to keratinocyte damage [3, 5]. Soluble Fas ligands, perforin, granzyme, and, recently, granulysin have been implicated in death of keratinocyte [6]. Drug metabolites also act as haptens, and defect in the detoxification system of clearing those haptons may be the cause of severe drug reactions [3].

As the patient was from a very rural area without proper healthcare, even without a medical doctor, the access to dermatologist was unimaginable. However, the mobile...
teledermatology assisted with proper diagnosis and management of the case. The foremost part in the management of such severe drug reaction was to stop the culprit drug. The specific treatment modalities in management are high dose of corticosteroid (though debated), cyclosporine, plasmapheresis, and intravenous immunoglobulins [7]. We abruptly stopped carbamazepine. As the patient had only access to systemic steroid and thus was advised to administer intravenous hydrocortisone which was later switched to oral prednisolone.

Teledermatology is increasingly being used worldwide in these pandemics situations than ever, and mobile teledermatology is its simple form. This could also be a dynamic tool for the remote areas where a dermatologist is not available, even in post-COVID era as well [8]. They could be life-saving, timesaving, and economical at times like our scenario [9].

Carbamazepine-induced TEN was successfully managed at the outreach center with the help of mobile teledermatology. Awareness about the drugs implicated in severe drug reactions would help to prevent these life-threatening drug reactions. Besides, the use of teledermatology would help the healthcare workers and medical officers with less exposure of dermatology in identifying and managing skin diseases.

**Consent**

Written informed consent was obtained from the guardian of the patient, as she was a minor, for the publication of this case report and the accompanying images.

**Conflicts of Interest**

The authors have no conflicts of interest regarding the publication of this article.

**Acknowledgments**

The authors would like to thank to the team of Nepal Help Community Health Centre and Mr. Prem Deuba, Health Assistant, for helping us managing the life-threatening case selflessly and successfully.

**References**

[1] A. Lyell, “Toxic epidermal necrolysis: an eruption resembling scalding of the skin,” *British Journal of Dermatology*, vol. 68, no. 11, pp. 355–361, 1956.

[2] T. Bettuzzi, L. Penso, N. De Prost et al., “Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017,” *British Journal of Dermatology*, vol. 182, no. 1, pp. 247–248, 2020.

[3] V. Harris, C. Jackson, and A. Cooper, “Review of toxic epidermal necrolysis,” *International Journal of Molecular Sciences*, vol. 17, no. 12, p. 2135, 2016.

[4] M.-S. Yang, J. Y. Lee, J. Kim et al., “Searching for the culprit drugs for stevens-johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea,” *The Journal of Allergy and Clinical Immunology: In Practice*, vol. 8, no. 2, pp. 690–695, 2020.

[5] R. A. Schwartz, P. H. McDonagh, and B. W. Lee, “Toxic epidermal necrolysis. Part I,” *Journal of the American Academy Dermatology*, vol. 69, no. 2, pp. 173.E1–173.E13, 2013.

[6] I. Viard-Leveugle, O. Gaide, D. Jankovic et al., “TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis,” *The Journal of Investigative Dermatology*, vol. 133, no. 2, pp. 489–498, 2013.

[7] Y. Kinoshita and H. Saeki, “A review of the active treatments for toxic epidermal necrolysis,” *Journal of Nippon Medical School*, vol. 84, no. 3, pp. 110–117, 2017.

[8] V. Paudel, “Tele-dermatology in clinical management of suspected cutaneous leishmaniasis in COVID-19 pandemic,” *Nepal Journal of Dermatology, Venereology & Leprology*, vol. 18, no. 1, pp. 91–92, 2020.

[9] S. Perkins, J. M. Cohen, C. A. Nelson, and C. G. Bunick, “Teledermatology in the era of COVID-19: experience of an academic department of dermatology,” *Journal of the American Academy of Dermatology*, vol. 83, no. 1, pp. E43–E44, 2020.